Found: 2
Select item for more details and to access through your institution.
Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study.
- Published in:
- Irish Journal of Medical Science, 2022, v. 191, n. 4, p. 1647, doi. 10.1007/s11845-021-02761-6
- By:
- Publication type:
- Article
Kolorektal Kanser Tanılı Hastalarda Sağkalımı Öngörmede Florodeoksiglukoz Pozitron Emisyon Tomografi/Bilgisayarlı Tomografive Serum Karsinoembriyojenik Antijen Değerinin Rolü.
- Published in:
- Nuclear Medicine Seminars, 2020, v. 6, p. 16
- By:
- Publication type:
- Article